CanSino Biologics Inc.

SEHK:6185 주식 보고서

시가총액: HK$10.6b

CanSino Biologics 과거 수익 실적

과거 기준 확인 0/6

CanSino Biologics's earnings have been declining at an average annual rate of -33.9%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 7.8% per year.

주요 정보

-33.9%

수익 성장률

-32.9%

EPS 성장률

Biotechs 산업 성장11.0%
매출 성장률7.8%
자기자본 수익률-14.6%
순이익-96.2%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20
Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07
The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06
Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07
Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

May 12
CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Jan 09
Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Sep 16
CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Aug 31
Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Aug 29
Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13
Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01
Is CanSino Biologics (HKG:6185) Using Too Much Debt?

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15
We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11
CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

수익 및 비용 분석

CanSino Biologics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

SEHK:6185 수익, 비용 및 수입 (CNY Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 24749-720572449
30 Jun 24635-867573486
31 Mar 24371-1,513619585
31 Dec 23357-1,483655638
30 Sep 23503-1,420573691
30 Jun 23431-1,763599793
31 Mar 23636-1,170569771
31 Dec 221,035-909544778
30 Sep 221,921106487772
30 Jun 222,868989434651
31 Mar 224,3322,050408766
31 Dec 214,3001,914329879
30 Sep 213,1051,113246908
30 Jun 212,082643187872
31 Mar 21488-388103659
31 Dec 2025-39795428
30 Sep 206-23975234
30 Jun 204-18964202
31 Mar 206-13579191
31 Dec 192-15765152
30 Sep 196-13766127
30 Jun 1911-15669122
31 Mar 199-1584089
31 Dec 189-13846114
31 Dec 179-641668
31 Dec 168-501052

양질의 수익: 6185 is currently unprofitable.

이익 마진 증가: 6185 is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: 6185 is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.

성장 가속화: Unable to compare 6185's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: 6185 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).


자기자본 수익률

높은 ROE: 6185 has a negative Return on Equity (-14.61%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기